Company intelligence / Profile preview

HyperGenomics

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

HyperGenomics was commissioned to develop epigenetic profiling signatures from blood with funding of up to $55,000 based on milestone completion over an eight-month period as of November 2011[1]. The technology was designed to determine specific epigenetic signatures from biopsies and blood to identify disease subtypes and guide therapeutic selection[1].

Therapeutic areas: Oncology
Modalities: Diagnostic platform (epigenetic profiling)
Industry: Molecular Diagnostics

Partnerships

Biomedicum Genomics OY (for sequencing and bioinformatics)

Beyond the preview

Go deeper on HyperGenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HyperGenomics.

Explore the full profile